Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-Ab™
Target-Humanized Mouse Models (HUGO-GT™)
Target-Humanized Mouse Models (CDS)
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Custom Model Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Preclinical Solutions
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic
Obesity
MASH & MASLD
Cardiovascular
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Retinal-related diseases
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Systemic Lupus Erythematosus
Drug Classification
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
iCyagen
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Company Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeBlogs & InsightsWhat Is a Fully Human Antibody Mouse Model, and How Does It Work?
HUGO-Ab

What Is a Fully Human Antibody Mouse Model, and How Does It Work?

Cyagen Technical Content Team | November 18, 2026
Advance Your Antibody Discovery Pipeline
Discover how Cyagen's HUGO-Ab™ mouse models can help you identify antibody candidates for your target.
Advance Your Antibody Discovery Pipeline
Contents
01. What Is a Fully Human Antibody Mouse Model, and How Does It Work? 02. What Is a Fully Human Antibody Mouse Model? 03. How Fully Human Antibody Mouse Models Are Made and How They Produce Antibodies 04. Types of Human Immunoglobulin Mice: How Platform Designs Differ 05. How the HUGO-Mab™ Mouse Is Built 06. When to Use a Fully Human Antibody Mouse Model for Discovery 07. Reference

What Is a Fully Human Antibody Mouse Model, and How Does It Work?

A fully human antibody mouse model carries human immunoglobulin (Ig) gene segments that enable its B cells to generate antibodies with human variable regions after immunization. Depending on the platform design, these antibodies may also contain human constant regions. In models that retain mouse constant regions, the selected human variable regions can be recombinantly expressed with human constant regions to generate fully human antibody candidates.

When therapeutic antibody discovery starts with a conventional mouse antibody, the selected antibody often requires humanization. This step can alter binding affinity and require further engineering. Fully human antibody mouse models bypass the conventional CDR-grafting humanization step and, alongside phage and yeast display, provide established routes for discovering human antibody candidates. The resulting candidates still require evaluation and, where necessary, further optimization for therapeutic development.

What Is a Fully Human Antibody Mouse Model?

In a fully human antibody mouse model, also called a human Ig mouse in this article, the mouse's own B cells rearrange human immunoglobulin (Ig) gene segments as they develop. This process generates a diverse set of antibody variable regions. In a conventional antibody, the heavy- and light-chain variable regions together form the antigen-binding site. Some fully human antibody mice retain mouse constant regions. To obtain a fully human antibody from these mice, researchers express the selected human variable regions with human constant regions. A fully human antibody can still elicit an anti-drug antibody response in patients.

The phrase "humanized antibody mouse model" can be ambiguous. In mouse antibody humanization, researchers first select an antibody from a conventional mouse. They then graft its complementarity-determining regions (CDRs) onto human variable-region frameworks and may retain selected mouse residues to preserve binding. The resulting molecule is a humanized antibody.

Figure 1. Two routes to therapeutic antibody candidates.
Figure 1. Two routes to therapeutic antibody candidates. The left panel shows antibody discovery using a fully human antibody mouse model. The right panel shows humanization of an antibody selected from a conventional mouse [1].

How Fully Human Antibody Mouse Models Are Made and How They Produce Antibodies

The fully human antibody mouse model is engineered once. Its offspring inherit the human gene segments and use them during B-cell development and the response to immunization.

  1. Human Ig genes are introduced into the germline. Depending on the platform, human gene segments replace their mouse counterparts at the native loci, be introduced as transgenes at other genomic locations, or be carried on artificial chromosomes. Endogenous mouse Ig genes may also be modified or inactivated to limit the production of murine antibody chains.
  2. The mouse's B cells generate and refine the repertoire. During B-cell development, V, D and J gene segments rearrange to form heavy-chain variable regions, while V and J segments rearrange to form light-chain variable regions. After immunization, somatic hypermutation introduces additional changes into the antibody variable regions. Selection within germinal centers can enrich B cells with higher-affinity receptors, a process known as affinity maturation. Class-switch recombination changes the heavy-chain constant region without changing the antigen-binding variable regions, thereby altering the antibody isotope and potentially its effector functions. In models retaining mouse constant regions, this switching occurs among murine isotypes.
  3. Antigen-specific antibodies are recovered and sequenced. Researchers monitor serum antibody titers and recover B cells from tissues such as the spleen or lymph nodes. They can generate hybridomas and screen the antibodies they produce, or screen individual B cells directly. Paired heavy- and light-chain variable-region sequences from selected clones can then be used for recombinant expression.
Figure 2. Antibody discovery and validation workflow using a fully human antibody mouse model.
Figure 2. Antibody discovery and validation workflow using a fully human antibody mouse model.

Types of Human Immunoglobulin Mice: How Platform Designs Differ

Two design choices shape the antibody repertoire and the format recovered from the mouse.

The first is how much of the antibody is human. Some platforms encode both human variable and constant regions. Others retain mouse constant regions, which can help preserve compatibility with the mouse B-cell development and signaling environment. The resulting antibodies contain human variable regions but murine constant regions in vivo, and can be reformatted with human constant regions for therapeutic development. To produce a fully human IgG from a model that retains mouse constant regions, researchers express the selected human variable regions with human constant regions.

The second is how the human genes are introduced. Some early models used randomly integrated minilocus transgenes containing a subset of human gene segments [2]. Other platforms replace variable-region genes at the native mouse loci or carry large human Ig loci on an artificial chromosome. In 2014 studies, researchers replaced mouse variable-region genes with their human counterparts at the native loci while retaining mouse constant regions. In the assays tested, these mice mounted antibody responses comparable to those of wild-type controls [3-4].

HUGO-Mab™, the fully human monoclonal antibody mouse model in Cyagen's HUGO-Ab™ family, illustrates how these choices work together.

Design axis Option What you gain What to watch
How much of the antibody is human Human variable regions, mouse constant regions Can support normal B-cell development A constant-region swap during expression
Human variable and constant regions Fully human antibodies produced in vivo Response kinetics can vary by strain
How the human genes get in Randomly integrated minilocus transgene Simpler to build Only the included gene segments are available
In situ replacement or artificial chromosome transfer Can accommodate large repertoires Regulatory context differs between designs

How the HUGO-Mab™ Mouse Is Built

Cyagen uses its TurboKnockout™ embryonic stem cell targeting technology to replace the heavy-chain, κ light-chain and λ light-chain variable-region loci in situ with their human counterparts while retaining mouse constant regions. Cyagen lists C57BL/6NCya, BALB/cAnCya and SJL backgrounds and recommends starting immunization at 6 to 8 weeks of age.

Cyagen reports serum IgG subclass profiles comparable to wild-type controls. In Cyagen's anti-PD-L1 case study, single-B-cell screening yielded 1,466 paired heavy- and light-chain variable-region sequences from one immunized HUGO-Mab™ mouse and 1,248 from one immunized wild-type C57BL/6N mouse. Of these, 413 and 142 pairs, respectively, had distinct CDR amino acid sequences. In a PD-L1 protein-binding ELISA, three HUGO-Mab™ clones and two wild-type clones had lower EC₅₀ values than atezolizumab. In a separate epitope-binning assay using biolayer interferometry, clone SAI-427-4 showed no detectable competition with atezolizumab for PD-L1 binding.

Figure 3. Microfluidic droplet sorting of PD-L1-specific antibody-secreting cells from one immunized wild-type C57BL/6N mouse (left) and one immunized HUGO-Mab™ mouse (right).
Figure 3. Microfluidic droplet sorting of PD-L1-specific antibody-secreting cells from one immunized wild-type C57BL/6N mouse (left) and one immunized HUGO-Mab™ mouse (right). Each dot represents one droplet analyzed by Cyto-Mine. The x-axis shows mean green fluorescence from donor-labeled PD-L1, and the y-axis shows mean red fluorescence from the acceptor-labeled anti-IgG probe. Red dots indicate droplets selected for sorting based on a fluorescence resonance energy transfer (FRET) signal consistent with secretion of PD-L1-specific IgG. Black dots indicate droplets classified as negative.

Antibodies produced by HUGO-Mab™ mice contain human heavy- and light-chain variable regions paired with mouse constant regions. To generate fully human antibody candidates, researchers can recombinantly express the naturally paired human variable regions with selected human heavy- and light-chain constant regions. The choice of human IgG subclass helps determine Fc function. The resulting candidates will go through testing for binding, biological activity and developability.

When to Use a Fully Human Antibody Mouse Model for Discovery

These models are useful when a program calls for naturally paired human heavy- and light-chain variable regions that have undergone affinity maturation in vivo. For membrane protein targets, the antigen format also matters. Immunization with cells displaying the target can help preserve extracellular epitopes in their membrane context.

Common light-chain models can also supply binding arms for bispecific antibodies. For example, Cyagen's HUGO-Light™ mouse pairs diverse human heavy-chain variable regions with a fixed human κ light-chain variable region. This allows researchers to select binding arms for two different targets that share the same light chain, simplifying light-chain pairing during bispecific antibody assembly.A common light chain can reduce light-chain mispairing during bispecific antibody assembly, but correct heavy-chain heterodimerization remains a separate engineering consideration. Strategies such as Knobs-into-Holes (KiH) may be used alongside common light-chain designs.

Figure 4. Common light-chain design and heavy-chain pairing in bispecific antibody assembly.
Figure 4. Common light-chain design and heavy-chain pairing in bispecific antibody assembly. In this schematic, anti-PD-1 and anti-VEGF heavy-chain variable regions each pair with the same human κ light-chain variable region. Knobs-into-holes (KiH) engineering at the Fc interface favors pairing of the two different heavy chains.

Immune tolerance can limit antibody responses against human antigens that share highly conserved epitopes with their mouse counterparts. In such cases, knockout of the endogenous mouse ortholog may help reduce this tolerance barrier. Cyagen's HUGO-Ab-eKO™ platform combines target-knockout mouse engineering with human antibody discovery models to support antibody generation against challenging, highly conserved targets. The suitability of this approach depends on the target's biological role and the specific immunization strategy.. Antigen design can focus the response, but the epitopes recognized by the recovered antibodies still depend on which B cells respond.

A fully human antibody mouse model allows researchers to recover human variable regions that have undergone selection in vivo. The model's design determines whether the antibodies produced in the mouse already contain human constant regions or require recombinant expression in the intended human IgG format. For each candidate, binding alone is not sufficient to establish therapeutic potential. Functional activity, specificity, and developability must be evaluated in the final antibody format intended for development.

👉 [Explore Cyagen's Fully Human Antibody Discovery Platform]

👉 [Discuss Your Antibody Discovery Project with Our Scientists]

Reference

[1] Mallbris L, Davies J, Glasebrook A, Tang Y, Glaesner W, Nickoloff BJ. Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care? J Clin Aesthet Dermatol. 2016 Jul;9(7):13-5. Epub 2016 Jul 1. PMID: 27672407; PMCID: PMC5022998.

[2] Taylor LD, Carmack CE, Schramm SR, Mashayekh R, Higgins KM, Kuo CC, Woodhouse C, Kay RM, Lonberg N. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res. 1992 Dec 11;20(23):6287-95. doi: 10.1093/nar/20.23.6287. PMID: 1475190; PMCID: PMC334518.

[3] Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, Huang TT, Poueymirou WT, Esau L, Meola M, Mikulka W, Krueger P, Fairhurst J, Valenzuela DM, Papadopoulos N, Yancopoulos GD. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5153-8. doi: 10.1073/pnas.1324022111. Epub 2014 Mar 25. PMID: 24706856; PMCID: PMC3986188.

[4] Macdonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, Frendewey D, Valenzuela DM, Giallourakis CC, Alt FW, Yancopoulos GD, Murphy AJ. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5147-52. doi: 10.1073/pnas.1323896111. Epub 2014 Mar 25. PMID: 24706858; PMCID: PMC3986150.

Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
What Is a Fully Human Antibody Mouse Model, and How Does It Work?
PepGen's DM1 Data: Splicing Correction and the Preclinical Questions Ahead
AMT-130 and HTT-Lowering Therapies: Lessons from Preclinical Huntington's Disease Models
iPSCs in Drug Development: Disease Modeling and Screening
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCompany OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2026 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research